BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lavelle EC, Ward RW. Mucosal vaccines - fortifying the frontiers. Nat Rev Immunol 2021. [PMID: 34312520 DOI: 10.1038/s41577-021-00583-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 101] [Article Influence: 90.0] [Reference Citation Analysis]
Number Citing Articles
1 Carlsen PH, Kjeldsen RB, Pedersen GK, Christensen D, Nielsen LH, Boisen A. Oral vaccination using microdevices to deliver α-GalCer adjuvanted vaccine afford a mucosal immune response. Journal of Controlled Release 2023;353:134-146. [DOI: 10.1016/j.jconrel.2022.11.015] [Reference Citation Analysis]
2 Oladipo EK, Akindiya OE, Oluwasanya GJ, Akanbi GM, Olufemi SE, Adediran DA, Bamigboye FO, Aremu RO, Kolapo KT, Oluwasegun JA, Awobiyi HO, Jimah EM, Irewolede BA, Folakanmi EO, Olubodun OA, Akintibubo SA, Odunlami FD, Ojo TO, Akinro OP, Hezikiah OS, Olayinka AT, Abiala GA, Idowu AF, Ogunniran JA, Ikuomola MO, Adegoke HM, Idowu UA, Olaniyan OP, Bamigboye OO, Akinde SB, Babalola MO. Bioinformatics analysis of structural protein to approach a vaccine candidate against Vibrio cholerae infection. Immunogenetics 2022;:1-16. [PMID: 36459183 DOI: 10.1007/s00251-022-01282-5] [Reference Citation Analysis]
3 Deimel LP, Liu X, Gilbert-Jaramillo J, Liu S, James WS, Sattentau QJ. Intranasal SARS-CoV-2 spike-based immunisation adjuvanted with polyethyleneimine elicits mucosal and systemic humoral responses in mice. J Immunol Methods 2022;511:113380. [PMID: 36306825 DOI: 10.1016/j.jim.2022.113380] [Reference Citation Analysis]
4 Martín-cruz L, Angelina A, Baydemir I, Bulut Ö, Subiza JL, Netea MG, Domínguez-andrés J, Palomares O. Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1066383] [Reference Citation Analysis]
5 Vij S, Thakur R, Rishi P. Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella. Expert Review of Vaccines 2022. [DOI: 10.1080/14760584.2022.2148661] [Reference Citation Analysis]
6 Ho H, Huang C, Yang C, Liu S, Chen H, Yu G, Chen J, Chuang T, Huang M. Formulation of SARS-CoV-2 Spike Protein with CpG Oligodeoxynucleotides and Squalene Nanoparticles Modulates Immunological Aspects Following Intranasal Delivery. Pharmaceutics 2022;14:2539. [DOI: 10.3390/pharmaceutics14112539] [Reference Citation Analysis]
7 Sun S, Li E, Zhao G, Tang J, Zuo Q, Cai L, Xu C, Sui C, Ou Y, Liu C, Li H, Ding Y, Li C, Lu D, Zhang W, Luo P, Cheng P, Gao Y, Tu C, Pitard B, Rosenecker J, Wang B, Liu Y, Zou Q, Guan S. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121907] [Reference Citation Analysis]
8 Chen L, Zhang H, Li M, Wu B, Zhang Z, Gong R. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1005321] [Reference Citation Analysis]
9 Joseph J. Trained Immunity as a Prospective Tool against Emerging Respiratory Pathogens. Vaccines 2022;10:1932. [DOI: 10.3390/vaccines10111932] [Reference Citation Analysis]
10 Ashhurst AS, Johansen MD, Maxwell JWC, Stockdale S, Ashley CL, Aggarwal A, Siddiquee R, Miemczyk S, Nguyen DH, Mackay JP, Counoupas C, Byrne SN, Turville S, Steain M, Triccas JA, Hansbro PM, Payne RJ, Britton WJ. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nat Commun 2022;13:6972. [DOI: 10.1038/s41467-022-34297-3] [Reference Citation Analysis]
11 Lee J, Khang D. Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.022] [Reference Citation Analysis]
12 Epis S, Varotto-boccazzi I, Manenti A, Rubolini D, Gabrieli P, Cattaneo GM, Gourlay L, Dapporto F, Monti M, Razzano I, Leonardi M, Matteo I, Recordati C, Bertola L, Fiorina P, Marvasi L, Montomoli E, Zuccotti G, Bandi C. Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106546] [Reference Citation Analysis]
13 Sengupta A, Al-otaibi N, Devito C, Lottersberger F, Hinkula J. Characterization of splenic and systemic immunity by differentially charged lipid adjuvants in enhancing post-intranasal immunization response against influenza.. [DOI: 10.21203/rs.3.rs-2210670/v1] [Reference Citation Analysis]
14 Nakahashi-ouchida R, Fujihashi K, Kurashima Y, Yuki Y, Kiyono H. Nasal vaccines: solutions for respiratory infectious diseases. Trends in Molecular Medicine 2022. [DOI: 10.1016/j.molmed.2022.10.009] [Reference Citation Analysis]
15 Yang J, Liu MQ, Liu L, Li X, Xu M, Lin H, Liu S, Hu Y, Li B, Liu B, Li M, Sun Y, Chen YQ, Shi ZL, Yan H. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern. Cell Mol Immunol 2022;19:1279-89. [PMID: 36220993 DOI: 10.1038/s41423-022-00929-3] [Reference Citation Analysis]
16 Khalid K, Hussain T, Jamil Z, Alrokayan KS, Ahmad B, Waheed Y. Vaccinomics-Aided Development of a Next-Generation Chimeric Vaccine against an Emerging Threat: Mycoplasma genitalium. Vaccines (Basel) 2022;10:1720. [PMID: 36298585 DOI: 10.3390/vaccines10101720] [Reference Citation Analysis]
17 Madhavan M, Ritchie AJ, Aboagye J, Jenkin D, Provstgaad-Morys S, Tarbet I, Woods D, Davies S, Baker M, Platt A, Flaxman A, Smith H, Belij-Rammerstorfer S, Wilkins D, Kelly EJ, Villafana T, Green JA, Poulton I, Lambe T, Hill AVS, Ewer KJ, Douglas AD. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine 2022;:104298. [PMID: 36229342 DOI: 10.1016/j.ebiom.2022.104298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Deifallah Yousif M, Felek A, Saydam M, Wilson S, Murdan S, Mawas F. Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells. Vaccine 2022;40:6055-63. [PMID: 36096970 DOI: 10.1016/j.vaccine.2022.08.064] [Reference Citation Analysis]
19 Wiarda JE, Trachsel JM, Sivasankaran SK, Tuggle CK, Loving CL. Intestinal single-cell atlas reveals novel lymphocytes in pigs with similarities to human cells. Life Sci Alliance 2022;5:e202201442. [PMID: 35995567 DOI: 10.26508/lsa.202201442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol 2022; 11(5): 221-236 [DOI: 10.5501/wjv.v11.i5.221] [Reference Citation Analysis]
21 Yamamoto T, Tanji M, Mitsunaga F, Nakamura S. Preclinical Study on SARS-CoV-2 Sublingual Vaccine with RBD Antigen and Poly(I:C) Adjuvant in Cynomolgus Macaques.. [DOI: 10.1101/2022.09.21.508816] [Reference Citation Analysis]
22 Guerra ENS, Castro VTD, Amorim dos Santos J, Acevedo AC, Chardin H. Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review. Front Immunol 2022;13:1006040. [DOI: 10.3389/fimmu.2022.1006040] [Reference Citation Analysis]
23 Graaf A, Petric PP, Sehl-Ewert J, Henritzi D, Breithaupt A, King J, Pohlmann A, Deutskens F, Beer M, Schwemmle M, Harder T. Cold-passaged isolates and bat-swine influenza a chimeric viruses as modified live-attenuated vaccines against influenza a viruses in pigs. Vaccine 2022:S0264-410X(22)01108-2. [PMID: 36137904 DOI: 10.1016/j.vaccine.2022.09.013] [Reference Citation Analysis]
24 Wei X, Rong N, Liu J. Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. Front Immunol 2022;13:993754. [DOI: 10.3389/fimmu.2022.993754] [Reference Citation Analysis]
25 Sengupta A, Al-otaibi N, Devito C, Lottersberger F, Hinkula J. Anionic and Cationic Lipid Adjuvants individually induce distinct adaptive Th1/Th2-type immunity in enhancing post-intranasal immunization response against influenza.. [DOI: 10.21203/rs.3.rs-2037306/v1] [Reference Citation Analysis]
26 Hoover AR, More S, Liu K, West CL, Valero TI, Yu N, Villalva C, Kumar A, Alleruzzo L, Lam SSK, Hode T, Papin JF, Chen WR. A novel biopolymer for mucosal adjuvant against respiratory pathogens.. [DOI: 10.1101/2022.09.07.506979] [Reference Citation Analysis]
27 O’neill A, Kala MP, Wah TC, Saron WA, Mantri CK, Rathore AP, Wang L, St. John AL. Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern.. [DOI: 10.1101/2022.09.09.507250] [Reference Citation Analysis]
28 Wellford SA, Moseman AP, Dao K, Wright KE, Chen A, Plevin JE, Liao TC, Mehta N, Moseman EA. Mucosal plasma cells are required to protect the upper airway and brain from infection. Immunity 2022:S1074-7613(22)00411-3. [PMID: 36137543 DOI: 10.1016/j.immuni.2022.08.017] [Reference Citation Analysis]
29 Lum FM, Torres-Ruesta A, Tay MZ, Lin RTP, Lye DC, Rénia L, Ng LFP. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol 2022. [PMID: 36064780 DOI: 10.1038/s41577-022-00775-4] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
30 Parriott JE, Stewart JP, Smith DD, Curran SM, Bauer CD, Wyatt TA, Phillips JA, Lyden E, Thiele GM, Vetro JA. Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after Respiratory Immunization. Pharmaceutics 2022;14:1843. [DOI: 10.3390/pharmaceutics14091843] [Reference Citation Analysis]
31 Mcgrath JJC, Rebuli ME, Cass SP, Loeb M, Jaspers I. Smoking and e-cigarette use: key variables in testing IgA-oriented intranasal vaccines. The Lancet Respiratory Medicine 2022;10:822-824. [DOI: 10.1016/s2213-2600(22)00263-6] [Reference Citation Analysis]
32 Chen S, Guan F, Candotti F, Benlagha K, Camara NOS, Herrada AA, James LK, Lei J, Miller H, Kubo M, Ning Q, Liu C. The role of B cells in COVID-19 infection and vaccination. Front Immunol 2022;13:988536. [DOI: 10.3389/fimmu.2022.988536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tukhvatulin AI, Gordeychuk IV, Dolzhikova IV, Dzharullaeva AS, Krasina ME, Bayurova EO, Grousova DM, Kovyrshina AV, Kondrashova AS, Avdoshina DV, Gulyaev SA, Gulyaeva TV, Moroz AV, Illarionova VV, Zorkov ID, Iliukhina AA, Shelkov AY, Botikov AG, Erokhova AS, Shcheblyakov DV, Esmagambetov IB, Zubkova OV, Tokarskaya EA, Savina DM, Vereveyko YR, Ungur AS, Naroditsky BS, Ishmukhametov AA, Logunov DY, Gintsburg AL. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerging Microbes & Infections. [DOI: 10.1080/22221751.2022.2119169] [Reference Citation Analysis]
34 Jensen O, Trivedi S, Li K, Aubé J, Hale JS, Ryan ET, Leung DT. Use of a MAIT Activating Ligand, 5-OP-RU, as a Mucosal Adjuvant in a Murine Model of Vibrio cholerae O1 Vaccination. PAI 2022;7:122-44. [DOI: 10.20411/pai.v7i1.525] [Reference Citation Analysis]
35 Mbongue JC, Vanterpool E, Firek A, Langridge WHR. Lipopolysaccharide-Induced Immunological Tolerance in Monocyte-Derived Dendritic Cells. Immuno 2022;2:482-500. [DOI: 10.3390/immuno2030030] [Reference Citation Analysis]
36 Chavda VP, Vora LK, Apostolopoulos V. Inhalable Vaccines: Can They Help Control Pandemics? Vaccines (Basel) 2022;10:1309. [PMID: 36016197 DOI: 10.3390/vaccines10081309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Izeli Portilho A, Araujo Correa V, Dos Santos Cirqueira C, De Gaspari E. Intranasal and Intramuscular Immunization with Outer Membrane Vesicles from Serogroup C Meningococci Induced Functional Antibodies and Immunologic Memory. Immunol Invest 2022;:1-20. [PMID: 35950702 DOI: 10.1080/08820139.2022.2107931] [Reference Citation Analysis]
38 Díaz-dinamarca DA, Salazar ML, Castillo BN, Manubens A, Vasquez AE, Salazar F, Becker MI. Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities. Pharmaceutics 2022;14:1671. [DOI: 10.3390/pharmaceutics14081671] [Reference Citation Analysis]
39 Pastor Y, Ghazzaui N, Hammoudi A, Centlivre M, Cardinaud S, Levy Y. Refining the DC-targeting vaccination for preventing emerging infectious diseases. Front Immunol 2022;13:949779. [DOI: 10.3389/fimmu.2022.949779] [Reference Citation Analysis]
40 Du G, Qin M, Sun X. Recent progress in application of nanovaccines for enhancing mucosal immune responses. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.010] [Reference Citation Analysis]
41 Zhu J, Jain S, Sha J, Batra H, Ananthaswamy N, Kilgore PB, Hendrix EK, Hosakote YM, Wu X, Olano JP, Kayode A, Galindo CL, Banga S, Drelich A, Tat V, Tseng CK, Chopra AK, Rao VB. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine. mBio 2022;:e0182222. [PMID: 35900097 DOI: 10.1128/mbio.01822-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Jacobsen H, Jiménez VC, Sitaras I, Bar-zeev N, Čičin-šain L, Higdon MM, Deloria-knoll M. Post-vaccination T cell immunity to omicron. Front Immunol 2022;13:944713. [DOI: 10.3389/fimmu.2022.944713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Szoka FC Jr. A hitchhiker's guide to mucosal and systemic immunity. Sci Transl Med 2022;14:eadc8697. [PMID: 35857822 DOI: 10.1126/scitranslmed.adc8697] [Reference Citation Analysis]
44 Foged C. Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout. Front Drug Deliv 2022;2. [DOI: 10.3389/fddev.2022.964298] [Reference Citation Analysis]
45 Adashi EY, Gruppuso PA. Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable. Am J Prev Med 2022:S0749-3797(22)00337-3. [PMID: 35906142 DOI: 10.1016/j.amepre.2022.06.009] [Reference Citation Analysis]
46 Abdoli M, Shafaati M, Ghamsari LK, Abdoli A. Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2. Virus Res 2022;319:198857. [PMID: 35820511 DOI: 10.1016/j.virusres.2022.198857] [Reference Citation Analysis]
47 Killough M, Rodgers AM, Ingram RJ. Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines (Basel) 2022;10:1100. [PMID: 35891262 DOI: 10.3390/vaccines10071100] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Meurens F, Renois F, Bouin A, Zhu J. SARS-CoV-2 Vaccination: What Can We Expect Now? Vaccines (Basel) 2022;10:1093. [PMID: 35891257 DOI: 10.3390/vaccines10071093] [Reference Citation Analysis]
49 Mat Rani NNI, Alzubaidi ZM, Butt AM, Mohammad Faizal NDF, Sekar M, Azhari H, Mohd Amin MCI. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers. WIREs Nanomed Nanobiotechnol 2022;14. [DOI: 10.1002/wnan.1784] [Reference Citation Analysis]
50 Jeyananthan V, Afkhami S, D'Agostino MR, Zganiacz A, Feng X, Miller MS, Jeyanathan M, Thompson MR, Xing Z. Differential Biodistribution of Adenoviral-Vectored Vaccine Following Intranasal and Endotracheal Deliveries Leads to Different Immune Outcomes. Front Immunol 2022;13:860399. [PMID: 35757753 DOI: 10.3389/fimmu.2022.860399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Graaf A, Petric PP, Sehl-ewert J, Henritzi D, Breithaupt A, King J, Pohlmann A, Deutskens F, Beer M, Schwemmle M, Harder T. Cold-passaged isolates and bat-swine influenza A chimeric viruses as modified live-attenuated vaccines against influenza A viruses in pigs.. [DOI: 10.1101/2022.06.20.496807] [Reference Citation Analysis]
52 Angulo C, Sanchez V, Delgado K, Monreal-Escalante E, Hernández-Adame L, Angulo M, Tello-Olea M, Reyes-Becerril M. Oral organic nanovaccines against bacterial and viral diseases. Microb Pathog 2022;169:105648. [PMID: 35728750 DOI: 10.1016/j.micpath.2022.105648] [Reference Citation Analysis]
53 Jensen O, Trivedi S, Li K, Aubé J, Hale JS, Ryan ET, Leung DT. Use of a MAIT activating ligand, 5-OP-RU, as a mucosal adjuvant in a murine model of Vibrio cholerae O1 vaccination.. [DOI: 10.1101/2022.06.17.496603] [Reference Citation Analysis]
54 Nair S, Wu Y, Nguyen TM, Fink K, Luo D, Ruedl C. Intranasal Delivery of RIG-I Agonist Drives Pulmonary Myeloid Cell Activation in Mice. Front Immunol 2022;13:910192. [DOI: 10.3389/fimmu.2022.910192] [Reference Citation Analysis]
55 Luria-pérez R, Sánchez-vargas LA, Muñoz-lópez P, Mellado-sánchez G. Mucosal Vaccination: A Promising Alternative Against Flaviviruses. Front Cell Infect Microbiol 2022;12:887729. [DOI: 10.3389/fcimb.2022.887729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Mckay PF, Zhou J, Frise R, Blakney AK, Bouton CR, Wang Z, Hu K, Samnuan K, Brown JC, Kugathasan R, Yeow J, Stevens MM, Barclay WS, Tregoning JS, Shattock RJ. Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets. Oxford Open Immunology 2022;3. [DOI: 10.1093/oxfimm/iqac004] [Reference Citation Analysis]
57 Sun S, Li E, Zhao G, Tang J, Zuo Q, Cai L, Xu C, Sui C, Ou Y, Liu C, Li H, Ding Y, Li C, Lu D, Zhang W, Luo P, Cheng P, Gao Y, Tu C, Pitard B, Rosenecker J, Wang B, Liu Y, Zou Q, Guan S. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge.. [DOI: 10.1101/2022.05.29.493866] [Reference Citation Analysis]
58 Fratzke AP, van Schaik EJ, Samuel JE. Immunogenicity and Reactogenicity in Q Fever Vaccine Development. Front Immunol 2022;13:886810. [DOI: 10.3389/fimmu.2022.886810] [Reference Citation Analysis]
59 Martinuzzi E, Benzaquen J, Guerin O, Leroy S, Simon T, Ilie M, Hofman V, Allegra M, Tanga V, Michel E, Boutros J, Maniel C, Sicard A, Glaichenhaus N, Czerkinsky C, Blancou P, Hofman P, Marquette CH. A Single Dose of BNT162b2 mRNA Vaccine Induces Airway Immunity in SARS-CoV-2 Naive and recovered COVID-19 subjects. Clin Infect Dis 2022:ciac378. [PMID: 35579991 DOI: 10.1093/cid/ciac378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity 2022;55:800-18. [PMID: 35545029 DOI: 10.1016/j.immuni.2022.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Doan TA, Forward T, Tamburini BAJ. Trafficking and retention of protein antigens across systems and immune cell types. Cell Mol Life Sci 2022;79:275. [PMID: 35505125 DOI: 10.1007/s00018-022-04303-4] [Reference Citation Analysis]
62 Ye ZW, Ong CP, Tang K, Fan Y, Luo C, Zhou R, Luo P, Cheng Y, Gray VS, Wang P, Chu H, Chan JF, To KK, Chen H, Chen Z, Yuen KY, Ling GS, Yuan S, Jin DY. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. Cell Mol Immunol 2022;19:588-601. [PMID: 35352010 DOI: 10.1038/s41423-022-00855-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
63 Zhu J, Jain S, Sha J, Batra H, Ananthaswamy N, Kilgore PB, Hendrix EK, Hosakote YM, Wu X, Olano JP, Kayode A, Galindo CL, Banga S, Drelich A, Tat V, Tseng CK, Chopra AK, Rao VB. A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine.. [DOI: 10.1101/2022.04.28.489809] [Reference Citation Analysis]
64 Pallett LJ, Maini MK. Liver-resident memory T cells: life in lockdown. Semin Immunopathol 2022. [PMID: 35482059 DOI: 10.1007/s00281-022-00932-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Lin X, Sheng Y, Zhang X, Li Z, Yang Y, Wu J, Su Z, Ma G, Zhang S. Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine. J Control Release 2022:S0168-3659(22)00232-2. [PMID: 35483639 DOI: 10.1016/j.jconrel.2022.04.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Fragoso-Saavedra M, Ramírez-Estudillo C, Peláez-González DL, Ramos-Flores JO, Torres-Franco G, Núñez-Muñoz L, Marcelino-Pérez G, Segura-Covarrubias MG, González-González R, Ruiz-Medrano R, Xoconostle-Cázares B, Gayosso-Vázquez A, Reyes-Maya S, Ramírez-Andoney V, Alonso-Morales RA, Vega-López MA. Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2. Front Immunol 2022;13:848054. [PMID: 35432364 DOI: 10.3389/fimmu.2022.848054] [Reference Citation Analysis]
67 Soraci L, Lattanzio F, Soraci G, Gambuzza ME, Pulvirenti C, Cozza A, Corsonello A, Luciani F, Rezza G. COVID-19 Vaccines: Current and Future Perspectives. Vaccines 2022;10:608. [DOI: 10.3390/vaccines10040608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
68 Flitter BA, Braun MR, Tucker SN. Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens. Vaccines 2022;10:593. [DOI: 10.3390/vaccines10040593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Shamseldin MM, Zani A, Kenney A, Evans J, Zeng C, Read KA, Caution K, Hall JM, Brown JM, Gunsch G, Corps KN, Chaiwatpongsakorn S, Mahesh K, Lu M, Deora R, Peeples ME, Li J, Oestreich KJ, Liu S, Yount JS, Dubey P. Prime-pull immunization of mice with a BcfA-adjuvanted vaccine elicits mucosal immunity and prevents SARS CoV-2 infection and pathology.. [DOI: 10.1101/2022.04.06.487394] [Reference Citation Analysis]
70 Kar S, Devnath P, Emran TB, Tallei TE, Mitra S, Dhama K. Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges. Immun Inflamm Dis 2022;10:e604. [PMID: 35349752 DOI: 10.1002/iid3.604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
71 Aileni M, Rohela GK, Jogam P, Soujanya S, Zhang B. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. Cells 2022;11:1182. [DOI: 10.3390/cells11071182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
72 Agnew HN, Brazel EB, Tikhomirova A, van der Linden M, Mclean KT, Paton JC, Trappetti C. Streptococcus pneumoniae Strains Isolated From a Single Pediatric Patient Display Distinct Phenotypes. Front Cell Infect Microbiol 2022;12:866259. [DOI: 10.3389/fcimb.2022.866259] [Reference Citation Analysis]
73 Vassallo M, Clement N, Lotte L, Manni S, Sindt A, Bertrand PM, Durant J. Prevalence and Main Clinical Characteristics of Fully Vaccinated Patients Admitted to Hospital for Delta Variant COVID-19. Front Med (Lausanne) 2022;9:809154. [PMID: 35308544 DOI: 10.3389/fmed.2022.809154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Tartour E, Johannes L. STxB as an Antigen Delivery Tool for Mucosal Vaccination. Toxins 2022;14:202. [DOI: 10.3390/toxins14030202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
75 Feng F, Wen Z, Chen J, Yuan Y, Wang C, Sun C. Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases. Viruses 2022;14:520. [DOI: 10.3390/v14030520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Timofeeva A, Sedykh S, Nevinsky G. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. Vaccines 2022;10:384. [DOI: 10.3390/vaccines10030384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Bolaños-martínez OC, Govea-alonso DO, Fragoso G, Sciutto E, Rosales-mendoza S. Carrot cells expressing the VP1 and VP2 poliovirus proteins effectively elicited mucosal immunity. Plant Cell Tiss Organ Cult 2022;148:545-556. [DOI: 10.1007/s11240-021-02205-0] [Reference Citation Analysis]
78 Bellier B, Saura A, Luján LA, Molina CR, Luján HD, Klatzmann D. A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity. Front Immunol 2022;13:837443. [DOI: 10.3389/fimmu.2022.837443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Piccaluga PP, Di Guardo A, Lagni A, Lotti V, Diani E, Navari M, Gibellini D. COVID-19 Vaccine: Between Myth and Truth. Vaccines 2022;10:349. [DOI: 10.3390/vaccines10030349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
80 Yuan Y, Gao X, Ni F, Xie W, Fu W, Zhang G, Hu H, Li Y, Hu Q, Huang C, Liu B, Liu Y, Shen Q, Liang M. A novel intranasal administration adenoviral vector-based platform for rapid COVID-19 vaccine development.. [DOI: 10.1101/2022.02.21.481247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Stolovich-rain M, Kumari S, Friedman A, Kirillov S, Socol Y, Billan M, Pal RR, Golding P, Oiknine-djian E, Sirhan S, Sagie MB, Cohen-kfir E, Elgrably-weiss M, Zhou B, Ravins M, Gatt YE, Das K, Zelig O, Wiener R, Wolf DG, Elinav H, Strahilevitz J, Padawer D, Baraz L, Rouvinski A. Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces robust neutralizing salivary IgA.. [DOI: 10.1101/2022.02.17.480851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Zhuo S, Wu J, Zhao L, Li W, Zhao Y, Li Y. A chitosan-mediated inhalable nanovaccine against SARS-CoV-2. Nano Res . [DOI: 10.1007/s12274-021-4012-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
83 Mangla B, Javed S, Sultan MH, Ahsan W, Aggarwal G, Kohli K. Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit. Front Pharmacol 2021;12:757761. [PMID: 35087403 DOI: 10.3389/fphar.2021.757761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Mohammed SA, Shaaban EIA. Efficacious nanomedicine track toward combating COVID-19. Nanotechnology Reviews 2022;11:680-98. [DOI: 10.1515/ntrev-2022-0036] [Reference Citation Analysis]
85 van der Ley PA, Zariri A, van Riet E, Oosterhoff D, Kruiswijk CP. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. Front Immunol 2021;12:781280. [PMID: 34987509 DOI: 10.3389/fimmu.2021.781280] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 16.0] [Reference Citation Analysis]
86 Berzosa M, Nemeskalova A, Zúñiga-ripa A, Salvador-bescós M, Larrañeta E, Donnelly RF, Gamazo C, Irache JM. Immune Response after Skin Delivery of a Recombinant Heat-Labile Enterotoxin B Subunit of Enterotoxigenic Escherichia coli in Mice. Pharmaceutics 2022;14:239. [DOI: 10.3390/pharmaceutics14020239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
87 Karczmarzyk K, Kęsik-brodacka M. Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines. Pathogens 2022;11:117. [DOI: 10.3390/pathogens11020117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
88 Wiarda JE, Trachsel JM, Sivasankaran SK, Tuggle CK, Loving CL. Porcine intestinal innate lymphoid cells and lymphocyte spatial context revealed through single-cell RNA sequencing.. [DOI: 10.1101/2022.01.09.475571] [Reference Citation Analysis]
89 Feng T, Nie C, Peng P, Lu H, Wang T, Li P, Huang W. Nanoagent-based theranostic strategies against human coronaviruses. Nano Res 2022;:1-15. [PMID: 35003529 DOI: 10.1007/s12274-021-3949-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Ghosh AJ, Sarkar S, Ghosh S, Saha T. Prebiotic Immunomodulators to Enhance Mucosal Immunity and to Reduce Mass Use of Antibiotics. Alternatives to Antibiotics 2022. [DOI: 10.1007/978-981-19-1854-4_17] [Reference Citation Analysis]
91 Anggraeni R, Ana ID, Wihadmadyatami H. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants. Clin Exp Vaccine Res 2022;11:235. [DOI: 10.7774/cevr.2022.11.3.235] [Reference Citation Analysis]
92 Tang W, Zhang Y, Zhu G. Pulmonary delivery of mucosal nanovaccines. Nanoscale 2021. [PMID: 34918733 DOI: 10.1039/d1nr06512b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
93 Martinuzzi E, Benzaquen J, Guerin O, Leroy S, Simon T, Ilie M, Hofman V, Allegra M, Tanga V, Michel E, Boutros J, Maniel C, Sicard A, Glaichenhaus N, Czerkinsky C, Blancou P, Hofman P, Marquette C. A Single Dose of COVID-19 mRNA Vaccine Induces Airway Immunity in COVID-19 Convalescent Patients.. [DOI: 10.1101/2021.12.16.21267932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Chatterjee SK, Saha S, Munoz MNM. Activation of mucosal immunity and novel prophylactic and therapeutic strategy in combating COVID-19. Explor Immunol 2021. [DOI: 10.37349/ei.2021.00025] [Reference Citation Analysis]
95 Hoffmann JC, Schön MP. Integrin αE(CD103)β7 in Epithelial Cancer. Cancers (Basel) 2021;13:6211. [PMID: 34944831 DOI: 10.3390/cancers13246211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
96 Karyal C, Palazi P, Hughes J, Griffiths RC, Persaud RR, Tighe PJ, Mitchell NJ, Griffin R. Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile. Vaccines (Basel) 2021;9:1453. [PMID: 34960199 DOI: 10.3390/vaccines9121453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol 2021. [PMID: 34873279 DOI: 10.1038/s41577-021-00657-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 50.0] [Reference Citation Analysis]
98 Hickey JW, Becker WR, Nevins SA, Horning A, Perez AE, Chiu R, Chen DC, Cotter D, Esplin ED, Weimer AK, Caraccio C, Venkataraaman V, Schürch CM, Black S, Brbić M, Cao K, Leskovec J, Zhang Z, Lin S, Longacre T, Plevitis SK, Lin Y, Nolan GP, Greenleaf WJ, Snyder M. High Resolution Single Cell Maps Reveals Distinct Cell Organization and Function Across Different Regions of the Human Intestine.. [DOI: 10.1101/2021.11.25.469203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
99 Enriquez AB, Izzo A, Miller SM, Stewart EL, Mahon RN, Frank DJ, Evans JT, Rengarajan J, Triccas JA. Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics. Front Immunol 2021;12:740117. [PMID: 34759923 DOI: 10.3389/fimmu.2021.740117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 McCright J, Ramirez A, Amosu M, Sinha A, Bogseth A, Maisel K. Targeting the Gut Mucosal Immune System Using Nanomaterials. Pharmaceutics 2021;13:1755. [PMID: 34834170 DOI: 10.3390/pharmaceutics13111755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, House T, Hay J, Bell JI, Newton JN, Farrar J, Crook D, Cook D, Rourke E, Studley R, Peto TEA, Diamond I, Walker AS. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021. [PMID: 34650248 DOI: 10.1038/s41591-021-01548-7] [Cited by in Crossref: 235] [Cited by in F6Publishing: 273] [Article Influence: 235.0] [Reference Citation Analysis]
102 Bellier B, Saura A, Luján LA, Molina CR, Lujan HD, Klatzmann D. A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity.. [DOI: 10.1101/2021.09.09.459634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Pandolfi S, Chirumbolo S. On reaching herd immunity during the COVID-19 pandemic and further issues. J Med Virol 2022;94:24-5. [PMID: 34491592 DOI: 10.1002/jmv.27322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K, House T, Hay J, Bell JI, Newton JN, Farrar J, Crook D, Cook D, Rourke E, Studley R, Peto T, Diamond I, Walker AS, the COVID-19 Infection Survey Team. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.. [DOI: 10.1101/2021.08.18.21262237] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 75.0] [Reference Citation Analysis]